DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ ...

Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...

The "Antibody Drug Conjugates Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering.World revenue for the Antibody Drug Conjugates Market is set to surpass US$16 billion in 2025 ...

Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m Daiichi Sankyo has finalised the acquisition of intellectual ...

AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients ...

AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan has been accepted by the U.S. FDA for treating ad ...

AstraZeneca AZN stock has declined 14% in the past three months. A lot of this price decline is due to ongoing investigations ...

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...

Russia halted natural-gas flows to Europe via Ukraine, as Kyiv’s refusal to extend a pipeline deal brought an end to one of the last remaining energy links between Russia and what was once its ...

Port Canaveral is working with the Florida Department of Transportation to study whether a fuel pipeline between the port and Orlando International Airport would be feasible. A similar pipeline ...

NEW YORK – AstraZeneca and Daiichi Sankyo last week said they have voluntarily withdrawn an application seeking approval in the EU for their TROP2-directed antibody-drug conjugate (ADC) datopotamab ...